MX2020001227A - Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. - Google Patents

Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.

Info

Publication number
MX2020001227A
MX2020001227A MX2020001227A MX2020001227A MX2020001227A MX 2020001227 A MX2020001227 A MX 2020001227A MX 2020001227 A MX2020001227 A MX 2020001227A MX 2020001227 A MX2020001227 A MX 2020001227A MX 2020001227 A MX2020001227 A MX 2020001227A
Authority
MX
Mexico
Prior art keywords
methods
recombinant polypeptide
detecting
cell lines
compositions
Prior art date
Application number
MX2020001227A
Other languages
English (en)
Inventor
Feny Gunawan
Yi- Chun HSIAO
Denise C Krawitz
Margaret S Lin
Martin Vanderlaan
Rajesh Vij
Inn H Yuk
Judith Zhu-Shimoni
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2020001227A publication Critical patent/MX2020001227A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Se proporcionan anticuerpos monoclonales y policlonales que se unen al homólogo 2 de la fosfolipasa B de hámster. También se proporcionan métodos para detectar y cuantificar el homólogo 2 de la fosfolipasa B de hámster, por ejemplo, en preparaciones de polipéptidos recombinantes, así como equipos para llevar a cabo tales métodos. También se proporcionan métodos para clasificar o seleccionar las líneas de células hospederas o líneas de células que expresan el polipéptido recombinante, que expresan bajos niveles del homólogo 2 de la fosfolipasa B de hámster.
MX2020001227A 2013-09-13 2016-03-03 Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. MX2020001227A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877503P 2013-09-13 2013-09-13
US201461991228P 2014-05-09 2014-05-09

Publications (1)

Publication Number Publication Date
MX2020001227A true MX2020001227A (es) 2020-07-20

Family

ID=52666515

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002799A MX2016002799A (es) 2013-09-13 2014-09-12 Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
MX2020001227A MX2020001227A (es) 2013-09-13 2016-03-03 Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016002799A MX2016002799A (es) 2013-09-13 2014-09-12 Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.

Country Status (13)

Country Link
US (3) US9945858B2 (es)
EP (2) EP3044323B1 (es)
JP (2) JP6546178B2 (es)
KR (2) KR102260855B1 (es)
CN (1) CN105722992B (es)
BR (1) BR112016004437A2 (es)
CA (2) CA2920686C (es)
ES (1) ES2915378T3 (es)
HK (1) HK1226107A1 (es)
MX (2) MX2016002799A (es)
PL (1) PL3044323T3 (es)
RU (1) RU2016107435A (es)
WO (1) WO2015038884A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
JP6865689B2 (ja) * 2015-03-06 2021-04-28 ジェネンテック， インコーポレイテッド 超精製ＤｓｂＡ及びＤｓｂＣ、ならびにそれらの作製及び使用方法
CN105021824A (zh) * 2015-07-06 2015-11-04 上海优者生物科技有限公司 用于定量检测生物医药制品中残留cho宿主细胞蛋白的elisa试剂盒及其使用方法
EP3500297A1 (en) 2016-08-16 2019-06-26 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
AU2017323583A1 (en) 2016-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited Methods for purifying antibodies
US11254753B2 (en) 2016-10-06 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Antibodies with reduced binding to process impurities
DK3532838T3 (da) 2016-10-25 2022-07-04 Regeneron Pharma Fremgangsmåder og systemer til kromatografidataanalyse
US11976121B2 (en) * 2017-07-20 2024-05-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. CD123-binding chimeric antigen receptors
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
IL272954B2 (en) 2017-09-19 2024-06-01 Regeneron Pharma Methods to reduce the generation of particles and preparations created by them
BR112020011797A2 (pt) * 2018-01-31 2020-11-17 Regeneron Pharmaceuticals, Inc. métodos para identificar a glucuronilação de um medicamento com proteína, para aumentar a pureza de um medicamento com proteína e para identificação de medicamento com proteína pós-translacional modificado, e, medicamento com proteína
TW202000891A (zh) 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CN109307771A (zh) * 2018-09-14 2019-02-05 北京三元基因药业股份有限公司 亲和层析定量检测重组人α干扰素工艺中间体含量的方法
GB201904741D0 (en) 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
KR20220010543A (ko) * 2019-05-21 2022-01-25 리제너론 파아마슈티컬스, 인크. 숙주 세포 단백질 동정 및 정량화 방법
EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
WO2024017826A2 (en) 2022-07-19 2024-01-25 Glaxosmithkline Intellectual Property Development Limited Methods for purifying recombinant polypeptides
KR102629162B1 (ko) 2022-11-04 2024-01-29 한국기초과학지원연구원 바이오의약품 품질관리를 위한 잔류 숙주세포 단백질 정량 분석 방법 및 시스템
CN117192107A (zh) * 2023-09-11 2023-12-08 福建基诺厚普生物科技有限公司 一种工艺特异性宿主细胞蛋白残留的检测方法及试剂盒

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0506826T3 (da) 1989-12-20 1996-05-13 Schering Corp Antistofantagonister mod humant interleukin-4
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP2865423B2 (ja) 1991-03-29 1999-03-08 エルフ・サノフィ サイトカイン型の活性を有するタンパク質、およびこのタンパク質をコード化する組換えｄｎａ、形質転換細胞および微生物
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2096289A1 (en) * 1992-05-15 1993-11-16 Wouter Musters Cloning and expression of dna encoding a ripening form of a polypeptide having rhamnogalacturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CA2142860A1 (en) 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
DE69415669T2 (de) * 1993-05-17 1999-07-01 Genentech, Inc., South San Francisco, Calif. Sialidase defiziente zellen
ES2143553T3 (es) 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2238080C (en) 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
ES2337091T3 (es) 1996-11-27 2010-04-20 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina.
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR200001246T2 (tr) 1997-01-10 2000-07-21 Biogen,Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi
EP0988056B1 (en) 1997-01-22 2003-07-09 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
CA2356779C (en) 1998-12-14 2012-03-13 Genetics Institute, Inc. Cytokine receptor chain
US6468528B1 (en) 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
EP1263785A2 (en) 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
US6761667B1 (en) 2000-02-02 2004-07-13 Icon Ip, Inc. Hiking exercise apparatus
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
WO2001064754A1 (fr) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Anticorps a recombinaison genique et son fragment
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
AU2002243443A1 (en) 2000-10-20 2002-07-24 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002051870A2 (en) 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
JP2005518336A (ja) * 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
DK1449850T3 (da) 2001-08-31 2011-02-14 Kyowa Hakko Kirin Co Ltd Humane CDR-graftede antistoffer eller antistoffragmenter deraf
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2464695A1 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
NZ532516A (en) 2001-11-07 2008-05-30 Cytos Biotechnology Ag Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
DE60239566D1 (de) 2002-06-14 2011-05-05 Brigham And Women S Hospital Boston Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
US20060147417A1 (en) 2002-08-30 2006-07-06 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
WO2004019975A2 (en) 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
EP2221317A3 (en) 2003-06-30 2011-07-27 Domantis Limited PEGylated single domain antibodies (dAb)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP2305833B1 (en) 2003-07-17 2014-04-16 Pacific Edge Limited Markers for detection of gastric cancer
SI1703893T1 (sl) 2003-12-23 2012-07-31 Genentech Inc Nova protitelesa proti il in uporaba le teh
JP5422101B2 (ja) * 2004-01-07 2014-02-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
WO2005071410A1 (en) * 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
US20070037966A1 (en) 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
JP5199063B2 (ja) 2005-03-11 2013-05-15 ワイス・エルエルシー 弱分配クロマトグラフィー方法
NZ562949A (en) 2005-04-11 2009-05-31 Medarex Inc Protein purification using HCIC and ion exchange chromatography
CA2623429C (en) 2005-09-30 2015-01-13 Medimmune Limited Interleukin-13 antibody composition
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
IL297746A (en) 2005-11-30 2022-12-01 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
PT2361638E (pt) 2005-12-12 2014-04-17 Ac Immune Sa Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas
UY30003A1 (es) 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
EP1966244B1 (en) * 2005-12-30 2012-03-21 Merck Patent GmbH Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
US7563875B2 (en) * 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
CN101454025B (zh) 2006-04-05 2014-01-01 艾伯维生物技术有限公司 抗体纯化
BRPI0710482A2 (pt) 2006-04-21 2011-08-16 Wyeth Corp métodos para seleção de alto rendimento de linhagens celulares
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
AR062947A1 (es) * 2006-09-21 2008-12-17 Verenium Corp Fosfolipasas acidos nucleicos que las codifican y metodos para prepararlas y usarlas
EP2074145B1 (en) 2006-10-02 2017-08-16 AC Immune S.A. Humanized antibody against amyloid beta
CN101523220B (zh) 2006-10-04 2016-09-21 健泰科生物技术公司 针对vegf的elisa
US20080299585A1 (en) 2006-12-18 2008-12-04 Paul Truex METHODS FOR DETECTION AND MEASUREMENT OF SECRETORY PHOSPHOLIPASE A2 LEVELS (sPLA2) IN BIOLOGICAL FLUIDS
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
PE20090831A1 (es) 2007-06-12 2009-07-10 Ac Immune Sa Anticuerpo monoclonal
EP2170389B1 (en) 2007-06-12 2014-10-29 AC Immune S.A. Humanized antibodies to amyloid beta
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
ES2612788T3 (es) 2007-10-05 2017-05-18 Genentech, Inc. Métodos y composiciones para el diagnóstico y tratamiento de la amiloidosis
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20110123530A1 (en) 2008-03-31 2011-05-26 Arron Joseph R Compositions and methods for treating and diagnosing asthma
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
KR101711798B1 (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
PL2322221T3 (pl) * 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
RU2514657C2 (ru) 2008-10-20 2014-04-27 Эббви Инк, Способ получения препарата антитела против il-18 или его антигенсвязывающей части (варианты)
JP2012506384A (ja) 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１２に結合する抗体およびそれを精製する方法
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
CN101979404B (zh) * 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
CA2770235C (en) 2009-08-06 2021-06-29 Genentech, Inc. Method to improve virus removal in protein purification
IN2015DN02826A (es) * 2009-09-03 2015-09-11 Merck Sharp & Dohme
UA109884C2 (uk) * 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
MX341136B (es) 2009-10-20 2016-08-09 Abbvie Inc Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a.
PL3342786T3 (pl) * 2010-01-29 2021-12-20 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
GEP20166442B (en) 2010-03-04 2016-03-10 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) * 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
HUE060541T2 (hu) * 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
SG10201503904XA (en) * 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
MX370828B (es) 2010-05-25 2020-01-08 Genentech Inc Métodos de purificación de polipéptidos.
JP2013533746A (ja) * 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
AU2011312425A1 (en) 2010-09-29 2013-04-11 Genentech, Inc. Antibody compositions and methods of use
KR102188544B1 (ko) 2010-11-30 2020-12-08 제넨테크, 인크. 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
RS57324B1 (sr) * 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
WO2013066866A1 (en) 2011-10-31 2013-05-10 Genentech, Inc. Antibody formulations
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
US9732156B2 (en) * 2012-02-29 2017-08-15 Gilead Biologics, Inc. Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
US10091883B2 (en) 2013-07-10 2018-10-02 Gemalto Sa Dielectric filmless electronic module and method for manufacturing same
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
CA3035343A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Also Published As

Publication number Publication date
CN105722992A (zh) 2016-06-29
CA2920686A1 (en) 2015-03-19
US9945858B2 (en) 2018-04-17
JP6546178B2 (ja) 2019-07-17
US20180364235A1 (en) 2018-12-20
PL3044323T3 (pl) 2022-06-27
KR20200133021A (ko) 2020-11-25
EP3044323A2 (en) 2016-07-20
JP2019197059A (ja) 2019-11-14
US10788494B2 (en) 2020-09-29
EP3044323A4 (en) 2017-07-05
EP3044323B1 (en) 2022-04-06
KR102332302B1 (ko) 2021-12-01
CA3174012A1 (en) 2015-03-19
WO2015038884A2 (en) 2015-03-19
MX2016002799A (es) 2016-05-26
HK1226107A1 (zh) 2017-09-22
CA2920686C (en) 2022-12-06
US20160320391A1 (en) 2016-11-03
KR20160054559A (ko) 2016-05-16
US11519912B2 (en) 2022-12-06
WO2015038884A3 (en) 2015-08-06
ES2915378T3 (es) 2022-06-22
CN105722992B (zh) 2021-04-20
BR112016004437A2 (pt) 2017-10-17
KR102260855B1 (ko) 2021-06-04
RU2016107435A (ru) 2017-10-18
EP4163633A1 (en) 2023-04-12
US20180364236A1 (en) 2018-12-20
JP2016531304A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
MX2015008045A (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano.
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
PH12017500489A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
MX2022007706A (es) Anticuerpos utiles en diagnosis de cancer.
BR112018004633A2 (pt) composições e métodos para detecção de proteínas
PH12015502807B1 (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
GB2541596A (en) Method and composition for determining specific antibody responses to species of filovirus
EP3306319A4 (en) TEST OBJECT DETECTION METHOD, AND IMMUNOLOGICAL ASSAY INSTRUMENT AND MONOCLONAL ANTIBODY THEREOF
MX2016012986A (es) Composiciones y metodos para identificar especies de ehrlichia.
WO2014159685A3 (en) Glatiramer acetate response biomarker mrna potency assay